Fas (Apo-1/CD95) is a cell-surface protein. It belongs to the myelodysplastic syndromes (MDS). We have studied Fas tumor necrosis factor (TNF) and nerve growth factor (NGF) (FAB) committee criterias. These patients included four refrac-
Fas expression intensity on CD34
+ cells negatively correlated to the BM blasts number (Spearman, P = 0.01) suggesting that role of Fas in the regulation of normal hematopoiesis is still tory anemia with ring sideroblasts (RARS), three refractory anemias (RA), 13 RA with excess of blasts (RAEB), three RAEB in transformation (RAEB-t) and four chronic myelomonocytic Introduction leukemias (CMML). Three patients with secondary acute myelogenous leukemias (AMLs) to myelodysplasia were also Myelodysplastic syndromes (MDS) are a heterogenous group studied. of clonally acquired hematopoietic stem cell disorders related to abnormal proliferation and differentiation of erythroid, myeloid, and megakaryocytic lineages, leading to trilineage BM cell preparation dysplasia. 1, 2 It was recently reported that bone marrow (BM) hematoBone marrow was harvested from healthy volunteers and poietic cells of MDS patients have increased apoptosis com-MDS patients by bone marrow aspirates. BMMC were isolated pared to normal BM cells. [3] [4] [5] This phenomenom is probably by density gradient centrifugation using a Ficoll lymphocyte important in the pathophysiology of the disease, and could separation medium. help to explain ineffective hematopoiesis observed in these syndromes. Plates were incubated at 37°C in a humidified incubator at 5% CO 2 in air. One Ci 3 H-TdR per well was added after The cell samples were analyzed on a XL cytometrer (Coulter).
24 h incubation, and cells were pulsed for an additional 16 h before 3 H-TdR uptake was determined by liquid scintillation Results were expressed as relative fluorescence intensity index (RFI), defined as the ratio of the fluorescence intensity counting. All experiments were performed in triplicate. Inhibition was considered to be significant if dose-dependent inhiof the Fas antigen to an isotypic-matched unrelated control antibody (Coulter). Mean RFI was defined for normal CD34 + , bition of DNA synthesis was observed at 100 ng/ml, 500 ng/ml, and 1000 ng/ml of CH-11 with more than 50% CD33 + , CD14 + , and glycophorin + BM cells. The signal intensity for Fas on cells from MDS patients was considered to be inhibition of 3 H incorporation at 500 ng/ml. increased if the RFI was above the value of (mean + 2 × s.d.) in normal controls (n = 8), suggesting a higher antigen density Clonogenic progenitor assays: Freshly isolated BMMC on the cell surface.
were plated in methylcellulose already containing IL-3, IL-6, SCF, EPO, and GM-CSF (methylcellulose StemGEM 1a; CNRS, Villejuif, France), supplemented with additional 2 U/ml EPO,
Hematopoietic cell cultures
and 50 ng/ml SCF, in the presence of either the anti-Fas MoAb (clone CH-11 at a concentration of 500, or 1000 ng/ml) or the Proliferation assays:
MNBM cells were resuspended in same concentrations of the isotypic control IgM MoAb. Total Iscove's modified Dulbecco's medium after washing in Hanks'
BMMC were plated at a density of 5 × 10 4 or 10 5 cells in 1 ml balanced salt solution (HBSS; GIBCO, Eragny, France), supmedium in 35-mm tissue culture dishes (Falcon; Becton plemented with 4 mg/ml bovine serum albumine (BSA; Sigma, Dickinson), and all experiments were performed in duplicate. St Louis, MO, USA), 2 mg/ml iron saturated transferrin Erythroid and myeloid colonies were enumerated after 14 (Sigma), 0.3 mg/ml L-glutamine, 100 U/ml penicillin G and days of culture. 0.1 mg/ml streptomycin, 4 U/ml erythropoietin (EPO, kindly provided by RW Johnson Pharmaceutical Research Institute at ORTHO Pharmaceutical, Raritan, NJ, USA), 50 ng/ml stem
Analysis of apoptosis
cell factor (SCF, Kirin Brewery Co, Tokyo, Japan), 100 U/ml interleukin-3 (IL-3; Kirin), and 5 ng/ml of granulocyte-macroIn situ cell death was detected on BM smears using the TUNEL technique (TDT-mediated dUTP nick end labelling) with the phage colony-stimulating factor (GM-CSF; Schering, France). + (t-PBS) for 20 min at room temperature. Slides were incubated in permeabilization solution (0.1% Triton X-100 in 0.1% sodium test, P = 0.158) cells. Figure 1 shows a typical histogram of Fas expression in a patient with MDS compared to the control. citrate) for 2 min on ice. The Tunel reaction mixture (terminal deoxynucleotidyl transferase (TDT), nucleotides containing Seven out of 25 MDS patients (28%) had a signal intensity for Fas on total BMMC that was stronger than in normal controls. fluorescein-labeled dUTP in reaction buffer) was added to samples. Smears protected with coverslips were incubated for Nine out of 25 patients (36%) had Fas overexpression on CD34 + , six out of 29 (20%) on CD33 + , nine out of 28 (32%) 1 h at 37°C. In negative controls, TDT was not used. The specimens were then incubated with anti-fluorescein antibody on glycophorin + , and 12 out of 20 (60%) on CD14 + cells (Figure 2 ). conjugated with horseradish peroxidase 30 min at 37°C. Finally, samples were stained using 3 × 3′ diaminobenzidine Great variability of Fas level expression was found between one patient and another without any correlation to the FAB tetrahydrochloride diluted in 0.05 M Tris buffer pH 7.8 with 0.05% H 2 O 2 , 5 min, shaded from light. After each step, slides subtype. A significant correlation between Fas expression on CD34 + and CD33 + BM cells was found (Spearman, P = 0.023). were rinsed three times in PBS. A Gill's hematoxylin countercoloration was used, and cells were analyzed by light microThe same correlation was observed for CD34 + and glycophorin + cells (Spearman, P = 0.018), and for CD34 + and scope. Cells with a light staining, which is confined to the nuclear periphery and has been described as the initiation of CD14 + cells (Spearman, P = 0.015). Moreover, there was a strong negative correlation between DNA fragmentation were not counted as positive. The percentage of these cells in controls was insignificant, and ranged Fas expression on CD34 + cells and the percentage of BM blast cells (Spearman, P = 0.01). Patients with low expression of Fas from 1 to 4% in MDS patients, justifying the exclusion.
Radiolabeled DNA ladder was performed as previously antigen on CD34 + cells had more BM blasts cells. We expected that Fas expression would be associated with described from 1 g of genomic DNA extracted from freshly isolated BMMC.
14 Briefly, 1 g cellular DNA was treated with cytopenias, but we did not find any correlation between Fas expression on CD34 + cells and the Bournemouth score. More-5 U of Klenow polymerase using 0.5 Ci of 32 P-labeled dCTP in the presence of 10 mM Tris-Hcl pH 7.5; 5 mM MgCl 2 . Then over Fas expression on myeloid CD33 + cells were not associated with neutropenia, nor was there any correlation between incubated for 10 min at room temperature and terminated after addition of 10 mM EDTA. The unincorporated nucleoFas expression on glycophorin + cells and the degree of anemia. tides were removed by three consecutive precipitation cycles of ammonium acetate (2.5 M final concentration/isopropanol) and the labeled DNA resuspended in 10 mM Tris/Hcl pH 7.5; 1 mM EDTA.
The Fas antigen is functional in vitro in patients with myelodysplasia

Statistical analysis
We first tested the capacity of a functional anti-Fas antibody (clone CH-11) to inhibit DNA synthesis of total BMMC culThe Student's t-test was used to compare quantitative data tured in short-term liquid culture. No dose-dependent inhiexpressed as means ± standard error of mean (s.e.m.). bition of DNA synthesis was observed in our culture conCorrelation between paired variables was studied using a ditions in three normal controls (data not shown). Seven MDS Spearman test.
patients (RA 1, RARS 3, RAEB 3) with different patterns of Fas expression on BM subpopulations were studied. As indicated in Table 2 Table 3 . Whereas the anti-Fas MoAb had no effect on colony expressed as the relative fluorescence intensity (RFI) of the formation in three normal controls (data not shown), patients anti-Fas Ab to the fluorescence of an irrelevant MoAb was 4 and 16 had dose-normal inhibition of both CFU-GM and 1.87 ± 0.12. The Fas protein was slightly expressed on CD33 + BFU-E colonies. In patient 6, Fas-mediated inhibition of BFUcells (mean RFI, 2.25 ± 0.77), whereas it was not or weakly E formation could not be studied because of ineffective expressed on CD34 + , (mean RFI, 0.65 ± 0.062), glycophorin gave a mean percentage of (12.6% ± 2.5) of apoptotic cells in patients. As shown in Table 1 and in Figure 3 , four out of 15 patients had a typical DNA ladder, indicative of advanced five normal BM.
Apoptosis of BM cells was statistically increased in patients stages of apoptosis. All these patients except one had more than 45% of apoptotic cells with TUNEL, indicative of massive with MDS compared to controls (mean 39% ± 5.7; t-test, P = 0.012). Programmed cell death (PCD) was mainly BM suicide. In none of the normal BM studied did we detect apoptosis with the radiolabeling DNA ladder test (data not observed in cells of the myeloid lineage from promyelocytes to neutrophils. Erythroid cells were also found in apoptosis shown). High rates of apoptosis with the TUNEL technique highly but to a lesser degree, and essentially at the stage of acidophil erythroblasts. In none of the patients did we identify megacorrelated to low Bournemouth score (Spearman, P = 0.01). All the patients with RAEB-t (3/3) or secondary AMLs (3/3) had karyocytes in apoptosis. Figure 3 shows typical pictures of apoptosis with the TUNEL technique. low apoptosis, whereas eight out of 11 (72%) patients with RAEB and two out of two patients with RA had massive We also used a sensitive radiolabeled DNA ladder technique to study apoptosis on freshly isolated BMMC in 15 apoptosis. Results are given as an inhibition index defined as the percentage of ( 3 H) uptake for a concentration of CH-11 of 500 ng/ml, as compared to an irrelevant isotype-matched myeloma protein at the same concentration. As explained in Methods, patients 2, 4, and 17 with dosedependent inhibition of DNA synthesis in the presence of 100 ng/ml, 500 ng/ml, or 1000 ng/ml of CH-11 and more than 50% inhibition of ( /ml freshly isolated BM cells were plated in methylcellulose in the presence of 1000 ng/ml of CH-11 or 1000 ng/ml of isotypematched myeloma protein. Results are expressed as percentage of inhibition defined as: (1− (number of BFU-E or CFU-GM colonies with CH-11/number of BFU-E or CFU-GM colonies with an irrelevant IgM MoAb)) × 100. Counts are given for duplicate cultures and colonies were enumerated at day 14. The arrow indicates Fas expression upregulation.
Finally, no statistical correlation could be identified between Fas expression and apoptosis with the TUNEL technique.
Discussion
The pathobiology of MDS continues to be enigmatic. Increased intramedullary apoptosis of BM hematopoietic cells recently described in patients with MDS could help to explain the association of peripheral cytopenias and BM hyperplasia generally reported in these disorders. [3] [4] [5] Such a process could implicate both hematopoietic and stromal cells. 3 We were interested in Fas antigen expression in a group of newly diagnosed MDS patients with different FAB subtypes. Fas is a cell surface receptor belonging to the TNF-R/NGF-R the control of normal hematopoiesis. 13 Moreover, Fasmediated apoptosis could be implicated in the pathophysiology of some hematological diseases. 15, 16 We showed in our study that Fas expression was statistically
Fas expression in about 50% of MDS patients, mostly on erythroblasts. We demonstrated that the Fas protein expressed was functional in vitro in three out of seven patients who showed DNA synthesis inhibition in the presence of CH-11. The three patients studied who expressed Fas on CD33 + and glycophorin + BM cells had Fas-mediated inhibition of CFU-GM colony formation in the presence of CH-11 (Table 3) , and in two cases, we could also show BFU-E inhibition. However, no inhibition was detected in patients 5, 12, and 19 whereas they expressed Fas on different BM populations (Table 2) . Moreover, patients 12 and 19 had very high rates of BM apoptosis (respectively 80 and 92%). These results suggest that other molecular mechanisms than Fas expression can explain increased apoptosis in MDS patients.
Apoptosis of bone marrow hematopoietic cells was detected in the present study by the TUNEL technique on BM smears. Our results confirm the importance of apoptosis in myelodysplasia. We found maximum rates of apoptosis in RA patients with RAEB-t or secondary AMLs had normal or low rates of apoptosis compared to controls. This process essentially affected cells of the myeloid lineage, from promyelocytes to mature neutrophils. Erythroid lineage was also TNF-alpha that mediate mitotic inhibitory pathways in hematopoietic progenitor cells can also induce Fas expression involved, but to a lesser degree, and at more advanced stages of differentiation. The reason why we did not identify megakaon CD34 + cells. 11, 12 High levels of TNF alpha observed in the bone marrow of many MDS patients 11, 12, 19 fragments, whereas TdT can in addition, label 5′ recessed and blunt-ended fragments. An important finding was that Fas expression on CD34 + progenitor cells negatively correlated to the percentage of bone Interestingly, high rates of apoptosis were observed in patients with low Bournemouth score. Recent data suggest marrow blasts (Spearman, P = 0.01). Patients with advanced stages of disease had lower Fas antigen intensity at the surface that RA and RAEB are proliferating diseases, and that a decrease in the proliferative capacity of myelopoiesis exists in of CD34
+ BM cells. Recent data suggest that Fas is expressed on leukemic cells of some patients with de novo AMLs, and advanced stages of MDS (RAEB-t and secondary AMLs). 24 Raza et al 3 showed that BM cells in MDS are simultaneously could define a group of good prognosis. 20 The prognostic value of Fas + vs Fas − CD34 + blast cells in term of complete engaged in apoptosis and DNA synthesis. RA and RAEB could be characterized by both increased remission in a large group of MDS patients treated with highdose chemotherapy should be evaluated.
proliferation and intensive intramedullary apoptosis. With disease progression, new oncogenic mechanisms operating in Unfortunately, Fas expression did not correlate to the FAB classification, the Bournemouth score, or peripheral cytopen-RAEB-t and secondary AMLs would lead to accumulation of blast cells with reduced proliferative capacity, block in differias. Regulation of apoptosis in the hematopoietic system is complex. It involves many gene products like p53, Bcl-2 entiation and low apoptosis. Reducing apoptosis in patients with low risk myelodysplasia and increased apoptosis could homologs associated with death induction and interacting proteins, c-myc, or cell death effectors like IL-1beta-conbe of important clinical value. In contrast restoration of effective molecular pathways of apoptosis in blast cells in verting enzyme (ICE) . 21 In advanced MDS, inactivation of the wild-type p53 protein by mutations is reported in 15% of advanced stages MDS could be a new approach to chemotherapy-combined treatment. cases and associated with a bad prognosis.
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